ArticleAnnals of surgical oncology2012
20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters.
Article in Annals of surgical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 74 citations in OpenAlex.
- Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.Cancer immunology research · 2018Trial
- Recombinant mutated human TNF in combination with chemotherapy for stage IIIB/IV non-small cell lung cancer: a randomized, phase III study.Scientific reports · 2015Trial
- Historical evaluation of clinical outcomes and safety following isolated limb perfusion for unresectable melanoma: Real-world data from the Mannheim Cancer Center.Therapeutic advances in medical oncology · 2026Article
- Isolated Limb Perfusion for Extremity Soft Tissue Sarcoma and Malignant Melanoma.Indian journal of surgical oncology · 2024Review
- Review
- OncogenicCancers · 2021Review
- The Role of Tumor Necrosis Factor in Manipulating the Immunological Response of Tumor Microenvironment.Frontiers in immunology · 2021Review
- RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma.EMBO molecular medicine · 2020Article
- Tumour necrosis factor signalling in health and disease.F1000Research · 2019Review
- Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression.Molecular therapy oncolytics · 2018Article
- Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy.British journal of cancer · 2018Article
- Trial Watch-Immunostimulation with cytokines in cancer therapy.Oncoimmunology · 2016Review
- TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature.British journal of cancer · 2015Article
- The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options.Cancers · 2015Review
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector.Molecular oncology · 2014Article
- Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation.World journal of surgical oncology · 2014Article
- Trial Watch: Immunostimulatory cytokines.Oncoimmunology · 2013Review
- Saikosaponin-d Enhances the Anticancer Potency of TNF-α via Overcoming Its Undesirable Response of Activating NF-Kappa B Signalling in Cancer Cells.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acids.Journal of drug delivery · 2013Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApproximately 5-8% of melanoma patients will develop in-transit metastases (IT-mets). Tumor necrosis factor-α (TNF) and melphalan-based isolated limb perfusion (TM-ILP) is an attractive treatment modality in melanoma patients with multiple IT-mets. This study reports on a 20 years experience and outlines the evolution and major changes since the introduction of TNF in ILP.
methodsA total of 167 TM-ILPs were performed in 148 patients, between 1991 and 2009. TM-ILPs were performed at high doses of TNF (3-4 mg) from 1991 to 2004 (n = 99) and at low doses of TNF (1-2 mg) from 2004 to 2009 (n = 68) under mild hyperthermic conditions (38°C-39.5°C.). Melphalan doses were unchanged at 10-13 mg/l (leg and arm, respectively). Characteristics for the 167 ILPs were: 81 stage IIIB, 65 stage IIIC, and 21 stage IV disease.
resultsThe overall response rate was 89% (n = 148). (Complete response [CR] = 61%; partial response [PR] = 28%). CR rates correlated with stage (P = .001) and with high-dose vs. low-dose TNF (70% vs. 49%; P < .006). High-dose TNF prolonged local control (median 16 months vs. 11 months; P = .076). Survival was not influenced by TNF dose. CR after ILP and number of lesions also correlated with local progression-free interval. Overall survival did correlate with stage of disease (P < .001), size of the lesions (P = .001), and a CR (P < .001).
conclusionsThis 2-decade single-center experience demonstrates that TM-ILP is a safe and effective treatment modality for melanoma patients with multiple IT-mets. Higher dose of TNF was associated with significantly higher CR rates and prolonged local control without an effect on overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.